EYPT Stock News & Catalysts – EyePoint Pharmaceuticals

FEATURED

EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings

WATERTOWN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal

Summary

Nov 6, 2026, 7:00 AM ·Globe Newswire

RECENT

EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026

WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal

Nov 5, 2026, 7:00 AM ·Globe Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ:EYPT). Such investors are advised to

Nov 3, 2026, 5:46 PM ·Globe Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ:EYPT). Such investors are advised to contact

Oct 29, 2026, 10:00 AM ·PRNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ:EYPT). Such investors are advised to

Oct 27, 2026, 5:58 PM ·Globe Newswire

EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky

NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT) shares fell roughly 80% after the Company disclosed that its Phase 3 LUCIA trial of DURAVYU missed its primary endpoint in wet

Oct 26, 2026, 11:46 AM ·Globe Newswire

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving EyePoint Pharmaceuticals (EYPT)

NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ:EYPT) shares have lost roughly 80% after the Phase 3 LUCIA trial of DURAVYU missed its primary endpoint in wet AMD. If you lost money on

Oct 22, 2026, 10:15 AM ·Globe Newswire

EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)

NEW YORK CITY, NY / ACCESS Newswire / October 21, 2026 / EyePoint Pharmaceuticals (NASDAQ:EYPT) shares fell roughly 80% after the Company reported that its Phase 3 LUCIA trial of DURAVYU in wet age-related macular

Oct 21, 2026, 10:10 AM ·ACCESS Newswire

EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals

EyePoint described its Phase 3 wet AMD trials as designed in close alignment with the FDA. LUCIA then missed its primary endpoint, and LUGANO's favorable result depended on excluding nine DURAVYU patients.NEW YORK,

Oct 20, 2026, 10:09 AM ·PRNewswire

EyePoint Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into EyePoint Pharmaceuticals (EYPT)

EyePoint Pharmaceuticals shares lost nearly 80% of their value following the disappointing Phase 3 LUCIA trial results for DURAVYU in wet age-related macular degeneration. Levi & Korsinsky is investigating potential

Oct 19, 2026, 5:58 PM ·PRNewswire

EyePoint Announces Strategic Prioritization

WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal

Oct 19, 2026, 7:15 AM ·Globe Newswire

EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD

– LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement – – Key secondary endpoints in LUCIA were

Oct 19, 2026, 7:00 AM ·Globe Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ:EYPT). Such investors are advised to contact

Sep 24, 2026, 5:34 PM ·PRNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ:EYPT). Such investors are advised to

Sep 22, 2026, 7:21 PM ·Globe Newswire

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal

Sep 16, 2026, 7:00 AM ·Globe Newswire

EyePoint Pharmaceuticals, Inc. EYPT · News